Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsLiabilities and Shareholders EquityLong-Term InvestmentsNon-Current AssetsOperating LeasesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Retained EarningsShareholder's EquityTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Lyell Immunopharma (LYEL) Non-Current Assets (2020 - 2025)

Lyell Immunopharma's Non-Current Assets history spans 6 years, with the latest figure at $79.8 million for Q3 2025.

  • For Q3 2025, Non-Current Assets fell 52.85% year-over-year to $79.8 million; the TTM value through Sep 2025 reached $414.9 million, down 38.89%, while the annual FY2024 figure was $111.3 million, 43.04% down from the prior year.
  • Non-Current Assets for Q3 2025 was $79.8 million at Lyell Immunopharma, down from $103.2 million in the prior quarter.
  • Across five years, Non-Current Assets topped out at $567.2 million in Q3 2021 and bottomed at $79.8 million in Q3 2025.
  • The 5-year median for Non-Current Assets is $218.5 million (2023), against an average of $258.6 million.
  • The largest annual shift saw Non-Current Assets soared 72.36% in 2021 before it crashed 52.85% in 2025.
  • A 5-year view of Non-Current Assets shows it stood at $501.1 million in 2021, then plummeted by 42.87% to $286.3 million in 2022, then plummeted by 31.76% to $195.3 million in 2023, then plummeted by 43.04% to $111.3 million in 2024, then fell by 28.31% to $79.8 million in 2025.
  • Per Business Quant, the three most recent readings for LYEL's Non-Current Assets are $79.8 million (Q3 2025), $103.2 million (Q2 2025), and $120.6 million (Q1 2025).